Molecular imaging of thyroid and parathyroid diseases

References

• Historical Timeline - SNMMI [Internet]. [cited 2024 Jan 27]. Available from: https://www.snmmi.org/AboutSNMMI/Content.aspx?ItemNumber=4175
   Google Scholar
• Campennì A, Avram AM, Verburg FA, et al. The EANM guideline on radioiodine therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2023 [cited 2023 Oct 2];50:[Internet]. 11):3324–3348. Available from: https://link.springer.com/article/10.1007/s00259-023-06274-5
   PubMed Web of Science ®Google Scholar
• Ravera S, Reyna-Neyra A, Ferrandino G, et al. The sodium/iodide symporter (nis): molecular physiology and preclinical and clinical applications. Annu Rev Physiol [Internet]. 2017 [cited 2024 Jan 27];79(1):261–289. Available from: https://pubmed.ncbi.nlm.nih.gov/28192058/
   PubMedGoogle Scholar
• Ramos CD, Zantut Wittmann DE, Sá De Camargo Etchebehere EC, et al. Thyroid uptake and scintigraphy using 99mTc pertechnetate: standardization in normal individuals. Sao Paulo Med J [Internet]. 2002 [cited 2024 Jan 27];120(2):45–48. Available from: https://pubmed.ncbi.nlm.nih.gov/11994772/
   PubMedGoogle Scholar
• Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med [Internet]. 2002 [cited 2024 Jan 27];43:1188–1200. Available from: https://pubmed.ncbi.nlm.nih.gov/12215558/
   PubMed Web of Science ®Google Scholar
• Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med [Internet]. 1990 [cited 2024 Jan 27];31:1646–1653. Available from: https://pubmed.ncbi.nlm.nih.gov/2213187/
   PubMed Web of Science ®Google Scholar
• O’Doherty MJ, Kettle AG, Wells P, et al. Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies. J Nucl Med. 1992;33(3):313–318.
   PubMed Web of Science ®Google Scholar
• Piwnica-Worms D, Holman BL. Noncardiac applications of hexakis(alkylisonitrile) technetium-99m complexes [Internet]. J Nucl Med. 1990 [cited 2024 Jan 27]:1166–1167. Available from: https://pubmed.ncbi.nlm.nih.gov/2362196/
   PubMed Web of Science ®Google Scholar
• Coakley AJ, Kettle AG, Wells CP, et al. 99Tcm sestamibi — a new agent for parathyroid imaging. Nuclear Medicine Communications [Internet]. 1989 [cited 2019 Dec 9];10(11):791–794. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2532313
   PubMed Web of Science ®Google Scholar
• Földes I, Lévay A, Stotz G. Comparative scanning of thyroid nodules with technetium-99m pertechnetate and technetium-99m methoxyisobutylisonitrile. Eur J Nucl Med [Internet]. 1993 [cited 2024 Jan 27];20(4):330–333. Available from: https://pubmed.ncbi.nlm.nih.gov/8387921/
   PubMedGoogle Scholar
• Listewnik MH, Piwowarska-Bilska H, Safranow K, et al. The diagnostic value of dual-phase SPECT/CT scintigraphy based on transport kinetics of 99mTc-sestamibi confirmed with histopathological findings in patients with secondary hyperparathyroidism — practical consideration. Nucl Med Rev Cent East Eur [Internet]. 2020 [cited 2024 Jan 27];23(2):71–77. Available from: https://pubmed.ncbi.nlm.nih.gov/33007093/
   PubMed Web of Science ®Google Scholar
• Sandrock D, Merino MJ, Norton JA, et al. Ultrastructural histology correlates with results of thallium-201/technetium-99m parathyroid subtraction scintigraphy. J Nucl Med [Internet]. 1993 [cited 2024 Jan 27];34:24–29. Available from: https://pubmed.ncbi.nlm.nih.gov/8418265/
   PubMed Web of Science ®Google Scholar
• Becker J, Schwarzenböck SM, Krause BJ. FDG PET hybrid imaging. recent, Results Cancer Res [Internet]. 2020 [cited 2024 Jan 27];216:625–667. Available from: https://pubmed.ncbi.nlm.nih.gov/32594401/
   Google Scholar
• Nanni C. PET-FDG: Impetus. Cancers (Basel) [Internet]. 2020 [cited 2024 Jan 27];12. Available from 4):1030. Available from: https://pubmed.ncbi.nlm.nih.gov/32331374/
   PubMed Web of Science ®Google Scholar
• Uehara M, Morita H. FDG-PET. Int Heart J [Internet]. 2023 [cited 2024 Jan 27];64(2):125–127. Available from: https://pubmed.ncbi.nlm.nih.gov/37005309/
   PubMed Web of Science ®Google Scholar
• Chierichetti F, Pizzolato G. 18F-FDG-PET/CT. Q J Nucl Med Mol Imaging [Internet]. 2012 [cited 2024 Jan 27];56:138–150. Available from: https://pubmed.ncbi.nlm.nih.gov/22617236/
   PubMed Web of Science ®Google Scholar
• Krause BJ, Schwarzenböck S, Souvatzoglou M. FDG PET and PET/CT. Recent Results Cancer Res [Internet]. 2013 [cited 2024 Jan 27];187:351–369. Available from: https://pubmed.ncbi.nlm.nih.gov/23179888/
   Google Scholar
• Kuker R, Sztejnberg M, Gulec S. I-124 Imaging and Dosimetry. Mol Imaging Radionucl Ther [Internet]. 2017 [cited 2024 Jan 27];26(1(1)):66–73. Available from: https://pubmed.ncbi.nlm.nih.gov/28117290/
   PubMedGoogle Scholar
• Jiang H, DeGrado TR. [18 F]Tetrafluoroborate ([18 F]TFB) and its analogs for PET imaging of the sodium/iodide symporter. Theranostics [Internet]. 2018 [cited 2021 Dec 2];8:3918–3931. Available from: https://pubmed.ncbi.nlm.nih.gov/30083270/
   PubMed Web of Science ®Google Scholar
• Podo F. Tumour phospholipid metabolism. NMR Biomed [Internet]. 1999 [cited 2024 Jan 27];12(7):413–439. Available from: https://pubmed.ncbi.nlm.nih.gov/10654290/
   PubMed Web of Science ®Google Scholar
• Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med [Internet]. 1998 [cited 2024 Jan 27];39:990–995. Available from: https://pubmed.ncbi.nlm.nih.gov/9627331/
   PubMed Web of Science ®Google Scholar
• Broos WAM, Wondergem M, van der Zant FM, et al. Dual-Time-Point 18F-Fluorocholine PET/CT in Parathyroid Imaging. J Nucl Med [Internet]. 2019 [cited 2024 Jan 27];60(11):1605–1610. Available from: https://pubmed.ncbi.nlm.nih.gov/30877179/
   PubMed Web of Science ®Google Scholar
• Orevi M, Freedman N, Mishani E, et al. Localization of parathyroid adenoma by 11C-choline PET/CT: preliminary results. Clin Nucl Med [Internet]. 2014 [cited 2019 Nov 13];39(12):1033–1038. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25290292
   PubMed Web of Science ®Google Scholar
• Rizzo A, Racca M, Cauda S, et al. 18F-fluorocholine PET/CT semi-quantitative analysis in patients affected by primary hyperparathyroidism: a comparison between laboratory and functional data. Endocrine [Internet]. 2023 [cited 2024 Jan 27];80(2):433–440. Available from: https://pubmed.ncbi.nlm.nih.gov/36495390/
   PubMed Web of Science ®Google Scholar
• Talbot JN, Périé S, Tassart M, et al. 18F-fluorocholine PET/CT detects parathyroid gland hyperplasia as well as adenoma: 401 PET/CTs in one center. Q J Nucl Med Mol Imaging [Internet]. 2023 [cited 2023 Nov 23];67(2):96–113. Available from: https://pubmed.ncbi.nlm.nih.gov/36995286/
   PubMed Web of Science ®Google Scholar
• Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med [Internet]. 2007 [cited 2024 Jan 27];48(4):508–518. Available from: https://pubmed.ncbi.nlm.nih.gov/17401086/
   PubMed Web of Science ®Google Scholar
• Sundin A, Arnold R, Baudin E, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology [Internet]. 2017 [cited 2024 Jan 27];105(3):212–244. Available from: https://pubmed.ncbi.nlm.nih.gov/28355596/
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, Krenning EP, Lebtahi R, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology [Internet]. 2009 [cited 2024 Jan 27];90(2):220–226. Available from: https://pubmed.ncbi.nlm.nih.gov/19713714/
   PubMed Web of Science ®Google Scholar
• Bushnell DL, Baum RP. Standard imaging techniques for neuroendocrine tumors. Endocrinol Metab Clin North Am [Internet]. 2011 [cited 2024 Jan 27];40(1):153–162. Available from: https://pubmed.ncbi.nlm.nih.gov/21349416/
   PubMed Web of Science ®Google Scholar
• Hennrich U, Benešová M. [68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging. Pharmaceuticals (Basel) [Internet]. 2020 [cited 2024 Jan 27];13. Available from: https://pubmed.ncbi.nlm.nih.gov/32138377/
   PubMedGoogle Scholar
• Yu J, Cao F, Zhao X, et al. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms. Neuroendocrinology [Internet]. 2022 [cited 2024 Jan 27];112:358–369. Available from: https://pubmed.ncbi.nlm.nih.gov/34077939/
   PubMed Web of Science ®Google Scholar
• Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med [Internet]. 2018 [cited 2024 Jan 27];59(1):66–74. Available from: https://pubmed.ncbi.nlm.nih.gov/29025982/
   PubMed Web of Science ®Google Scholar
• Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. Eur J Nucl Med Mol Imaging [Internet]. 2017 [cited 2020 Dec 1];44(9):1588–1601. Available from: https://doi.org/10.1007/s00259-017-3728-y
   PubMed Web of Science ®Google Scholar
• Zanzonico P. Principles of nuclear medicine imaging: planar, SPECT, PET, multi-modality, and autoradiography systems. Radiat Res [Internet]. 2012 [cited 2024 Jan 28];177(4):349–364. Available from: https://pubmed.ncbi.nlm.nih.gov/22364319/
   PubMed Web of Science ®Google Scholar
• Ljungberg M, Pretorius PH. SPECT/CT: an update on technological developments and clinical applications. Br J Radiol [Internet]. 2018 [cited 2024 Jan 28];91. Available from 1081):20160402. Available from: https://pubmed.ncbi.nlm.nih.gov/27845567/
   PubMed Web of Science ®Google Scholar
• Buck AK, Nekolla S, Ziegler S, et al. SPECT/CT. J Nucl Med [Internet]. 2008 [cited 2024 Jan 28];49(8):1305–1319. Available from: https://pubmed.ncbi.nlm.nih.gov/18632825/
   PubMed Web of Science ®Google Scholar
• Mallick R, Malik J, Yip L, et al. Novel Findings on SPECT-CT Tc-99 Sestamibi Imaging for Primary Hyperparathyroidism. J surg res [Internet]. 2020 [cited 2024 Jan 28];252:216–221. Available from: https://pubmed.ncbi.nlm.nih.gov/32289578/
   PubMed Web of Science ®Google Scholar
• Vaquero JJ, Kinahan P. Positron Emission Tomography: Current Challenges and Opportunities for Technological Advances in Clinical and Preclinical Imaging Systems. Annu Rev Biomed Eng [Internet]. 2015 [cited 2024 Jan 28];17(1):385–414. Available from: https://pubmed.ncbi.nlm.nih.gov/26643024/
   PubMedGoogle Scholar
• Rausch I, Cal-González J, Dapra D, et al. Performance evaluation of the Biograph mCT Flow PET/CT system according to the NEMA NU2-2012 standard. EJNMMI Phys [Internet]. 2015 [cited 2024 Jan 28];2(1):1–17. Available from: https://pubmed.ncbi.nlm.nih.gov/26501827/
   PubMedGoogle Scholar
• Petranović Ovčariček P, Görges R, Giovanella L. Autoimmune Thyroid Diseases. Semin Nucl Med [Internet]. 2023 [cited 2023 Dec 30]. Available from: https://pubmed.ncbi.nlm.nih.gov/38044176/
   PubMed Web of Science ®Google Scholar
• Giovanella L, Ovčariček P P. Functional and molecular thyroid imaging. The quarterly journal of nuclear medicine and molecular imaging [Internet]. The Q J Nucl Med and Mol Imaging. 2022 [cited 2024 Jan 6];66(2):86–92. Available from: https://pubmed.ncbi.nlm.nih.gov/35166094/
   PubMed Web of Science ®Google Scholar
• Petranović Ovčariček P, Deandreis D, Giovanella L. Thyroid dysfunctions induced by molecular cancer therapies: a synopsis for nuclear medicine thyroidologists. Eur J Nucl Med and Molecular Imaging 2021 [Internet]. 2021 [cited 2021 Jul 19];1–6. Available from: https://link.springer.com/article/10.1007/s00259-021-05394-0
   Google Scholar
• Giovanella L, Avram AM, Ovčariček PP, et al. Thyroid functional and molecular imaging. Presse Med [Internet]. 2022 [cited 2024 Jan 6];51. Available from 2):104116. Available from: https://pubmed.ncbi.nlm.nih.gov/35124101/
   PubMed Web of Science ®Google Scholar
• Scappaticcio L, Trimboli P, Keller F, et al. Diagnostic testing for graves’ or non-graves’ hyperthyroidism: a comparison of two thyrotropin receptor antibody immunoassays with thyroid scintigraphy and ultrasonography. Clin Endocrinol (Oxf). 2020;92(2):169–178. doi: 10.1111/cen.14130
   PubMed Web of Science ®Google Scholar
• Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. J Am Coll Radiol [Internet]. 2017 [cited 2023 Oct 25];14(5):587–595. Available from: https://pubmed.ncbi.nlm.nih.gov/28372962/
   PubMed Web of Science ®Google Scholar
• Zhou JQ, Yin LX, Wei X, et al. 2020 Chinese guidelines for ultrasound malignancy risk stratification of thyroid nodules: the C-TIRADS. Endocrine [Internet]. 2020 [cited 2023 Oct 25];70(2):256–279. Available from: https://pubmed.ncbi.nlm.nih.gov/32827126/
   PubMed Web of Science ®Google Scholar
• Russ G, Bonnema SJ, Erdogan MF, et al. European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS. Eur Thyroid J [Internet]. 2017 [cited 2022 Aug 31];6(5):225–237. Available from: https://pubmed.ncbi.nlm.nih.gov/29167761/
   PubMed Web of Science ®Google Scholar
• Seifert P, Schenke S, Zimny M, et al. Diagnostic Performance of Kwak, EU, ACR, and Korean TIRADS as Well as ATA Guidelines for the Ultrasound Risk Stratification of Non-Autonomously Functioning Thyroid Nodules in a Region with Long History of Iodine Deficiency: A German Multicenter Trial. Cancers (Basel) [Internet]. 2021 [cited 2023 Oct 25];13(17):4467. Available from: https://pubmed.ncbi.nlm.nih.gov/34503277/
   PubMed Web of Science ®Google Scholar
• Giovanella L, Campennì A, Tuncel M, et al. Integrated Diagnostics of Thyroid Nodules. Cancers (Basel) [Internet]. 2024 [cited 2024 Feb 24];16. Available from 2):311. Available from: https://pubmed.ncbi.nlm.nih.gov/38254799/
   PubMed Web of Science ®Google Scholar
• Schenke SA, Groener D, Grunert M, et al. Integrated Thyroid Imaging: Ultrasound and Scintigraphy. In: Giovanella L, editor. Integrated Diagnostics and Theranostics of Thyroid Diseases [Internet]. Cham: Springer; 2023 [cited 2023 Dec 21]. p. 25–62. Available from: https://link.springer.com/chapter/10.1007/978-3-031-35213-3_4
   Google Scholar
• Kreissl MC, Ovčariček PP, Campenni A, et al. The European Association of Nuclear Medicine (EANM)’s Response to the 2023 European Thyroid Association (ETA) clinical practice guidelines for thyroid nodule management and nuclear medicine: a deliberate oversight?. Eur J Nucl Med Mol Imaging [Internet]. 2024 [cited 2024 Feb 25]. Available from: https://pubmed.ncbi.nlm.nih.gov/38226985/
   PubMed Web of Science ®Google Scholar
• Ali SZ, Baloch ZW, Cochand-Priollet B, et al. The 2023 Bethesda System for Reporting Thyroid Cytopathology. Thyroid [Internet]. 2023 [cited 2023 Oct 21];33. Available from: https://pubmed.ncbi.nlm.nih.gov/37427847/
   PubMedGoogle Scholar
• Rossi ED, Locantore P, Bruno C, et al. Molecular Characterization of Thyroid Follicular Lesions in the Era of “Next-Generation” Techniques. Front Endocrinol [Internet]. 2022 [cited 2024 Feb 24];13. Available from: https://pubmed.ncbi.nlm.nih.gov/35634500/
   Web of Science ®Google Scholar
• Giovanella L, Ceriani L, Treglia G. Role of isotope scan, including positron emission tomography/computed tomography, in nodular goitre. Best Pract Res Clin Endocrinol Metab [Internet]. 2014 [cited 2021 Nov 20];28(4):507–518. Available from: https://pubmed.ncbi.nlm.nih.gov/25047202/
   PubMed Web of Science ®Google Scholar
• Hurtado-López LM, Arellano-Montaño S, Torres-Acosta EM, et al. Combined use of fine-needle aspiration biopsy, MIBI scans and frozen section biopsy offers the best diagnostic accuracy in the assessment of the hypofunctioning solitary thyroid nodule. Eur J Nucl Med Mol Imaging [Internet]. 2004 [cited 2023 Oct 23];31(9):1273–1279. Available from: https://pubmed.ncbi.nlm.nih.gov/15133637/
   PubMed Web of Science ®Google Scholar
• Giovanella L, Campenni A, Treglia G, et al. Molecular imaging with (99m)Tc-MIBI and molecular testing for mutations in differentiating benign from malignant follicular neoplasm: a prospective comparison. Eur J Nucl Med Mol Imaging [Internet]. 2016 [cited 2021 Nov 20];43(6):1018–1026. Available from: https://pubmed.ncbi.nlm.nih.gov/26695504/
   PubMed Web of Science ®Google Scholar
• Campennì A, Giovanella L, Siracusa M, et al. (99m)Tc-Methoxy-Isobutyl-Isonitrile Scintigraphy Is a Useful Tool for Assessing the Risk of Malignancy in Thyroid Nodules with Indeterminate Fine-Needle Cytology. Thyroid [Internet]. 2016 [cited 2021 Nov 20];26:1101–1109. Available from: https://pubmed.ncbi.nlm.nih.gov/27266385/
   PubMed Web of Science ®Google Scholar
• Saggiorato E, Angusti T, Rosas R, et al. 99mTc-MIBI Imaging in the presurgical characterization of thyroid follicular neoplasms: relationship to multidrug resistance protein expression. J Nucl Med [Internet]. 2009 [cited 2023 Oct 23];50(11):1785–1793. Available from: https://pubmed.ncbi.nlm.nih.gov/19837765/
   PubMed Web of Science ®Google Scholar
• Hervás Morón A. PET-CT in oncology. Clin Transl Oncol [Internet]. 2007 [cited 2023 Oct 23];9(8):473–474. Available from: https://pubmed.ncbi.nlm.nih.gov/17720648/
   PubMedGoogle Scholar
• Castellana M, Trimboli P, Piccardo A, et al. Performance of 18 F-FDG PET/CT in Selecting Thyroid Nodules with Indeterminate Fine-Needle Aspiration Cytology for Surgery. A Systematic Review and a Meta-Analysis. JCM [Internet]. 2019 [cited 2021 Nov 20];8(9):1333. Available from: https://pubmed.ncbi.nlm.nih.gov/31466411/
   Google Scholar
• Vriens D, De Wilt JHW, Van Der Wilt GJ, et al. The role of [18 F]-2-fluoro-2-deoxy-d-glucose–positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy. Cancer [Internet]. 2011 [cited 2021 Nov 20];117(20):4582–4594. Available from: https://pubmed.ncbi.nlm.nih.gov/21432844/
   PubMed Web of Science ®Google Scholar
• Wang N, Zhai H, Lu Y. Is fluorine-18 fluorodeoxyglucose positron emission tomography useful for the thyroid nodules with indeterminate fine needle aspiration biopsy? A meta-analysis of the literature. J Otolaryngol Head Neck Surg [Internet]. 2013 [cited 2021 Nov 20];42. Available from 1). Available from: https://pubmed.ncbi.nlm.nih.gov/24228840/
   Google Scholar
• de Koster Ej, de Geus-Oei Lf, Brouwers AH, et al. [18F]FDG-PET/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial. Eur J Nucl Med Mol Imaging [Internet]. 2022 [cited 2023 Nov 21];49(6):1970–1984. Available from: https://pubmed.ncbi.nlm.nih.gov/34981165/.
   PubMed Web of Science ®Google Scholar
• Giovanella L, Milan L, Piccardo A, et al. Radiomics analysis improves 18FDG PET/CT-based risk stratification of cytologically indeterminate thyroid nodules. Endocrine [Internet]. 2022 [cited 2021 Oct 16];75(1):202–210. Available from: https://link.springer.com/article/10.1007/s12020-021-02856-1
   PubMed Web of Science ®Google Scholar
• de Koster EJ, Noortman WA, Mostert JM, et al. Quantitative classification and radiomics of [18F]FDG-PET/CT in indeterminate thyroid nodules. Eur J Nucl Med Mol Imaging [Internet]. 2022 [cited 2023 Oct 25];49(7):2174–2188. Available from: https://pubmed.ncbi.nlm.nih.gov/35138444/
   PubMed Web of Science ®Google Scholar
• Giovanella L, Deandreis D, Vrachimis A, et al. Molecular Imaging and Theragnostics of Thyroid Cancers. Cancers (Basel) [Internet]. 2022 [cited 2023 Jan 21];14(5):1272. Available from: https://pubmed.ncbi.nlm.nih.gov/35267580/
   PubMed Web of Science ®Google Scholar
• Campennì A, Barbaro D, Guzzo M, et al. Personalized management of differentiated thyroid cancer in real life - practical guidance from a multidisciplinary panel of experts. Endocrine [Internet]. 2020 [cited 2023 Apr 5];70:280–291. Available from: https://pubmed.ncbi.nlm.nih.gov/32772339/
   PubMed Web of Science ®Google Scholar
• Avram AM, Giovanella L, Greenspan B, et al. SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version. J Nucl Med [Internet]. 2022 [cited 2022 Jun 2];63(6):15N–35N. Available from: https://pubmed.ncbi.nlm.nih.gov/35649660/
   PubMedGoogle Scholar
• Aide N, Heutte N, Rame JP, et al. Clinical relevance of single-photon emission computed tomography/computed tomography of the neck and thorax in postablation (131)I scintigraphy for thyroid cancer. The Journal of Clinical Endocrinology & Metabolism [Internet]. 2009 [cited 2021 Nov 20];94(6):2075–2084. Available from: https://pubmed.ncbi.nlm.nih.gov/19276233/
   PubMed Web of Science ®Google Scholar
• Avram AM. Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification. J Nucl Med [Internet]. 2012 [cited 2021 Nov 20];53(5):754–764. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22550280
   PubMed Web of Science ®Google Scholar
• Barbaro D, Campennì A, Forleo R, et al. False-positive radioiodine uptake after radioiodine treatment in differentiated thyroid cancer. Endocrine [Internet]. 2023 [cited 2024 Feb 24];81(1):30–35. Available from: https://pubmed.ncbi.nlm.nih.gov/36928601/
   PubMed Web of Science ®Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid [Internet]. 2016 [cited 2022 Feb 16];26(1):1–133. Available from: https://pubmed.ncbi.nlm.nih.gov/26462967/
   PubMed Web of Science ®Google Scholar
• Giovanella L, Trimboli P, Campenni A, et al. Thyroid and Parathyroid Cancer. In: Neri E Erba A, editors. Multimodality Imaging and Intervention in Oncology [Internet]. Cham: Springer; 2023 [cited 2024 Feb 24]. p. 45–79. Available from: https://link.springer.com/chapter/10.1007/978-3-031-28524-0_5
   Google Scholar
• Avram AM, Esfandiari NH, Wong KK. Preablation 131-I scans with SPECT/CT con tri bu te to thyroid cancer risk stratification and 131-I therapy planning. J Clin Endocrinol Metab [Internet]. 2015 [cited 2022 Jun 19];100(5):1895–1902. Available from: https://pubmed.ncbi.nlm.nih.gov/25734251/
   PubMed Web of Science ®Google Scholar
• Avram AM, Lm FG, Frey KA, et al. Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging?. The Journal of Clinical Endocrinology & Metabolism [Internet]. 2013 [cited 2021 Nov 20];98(3):1163–1171. Available from: https://pubmed.ncbi.nlm.nih.gov/23430789/
   PubMed Web of Science ®Google Scholar
• Spanu A, Solinas ME, Chessa F, et al. 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging. J Nucl Med [Internet]. 2009 [cited 2024 Feb 24];50(2):184–190. Available from: https://pubmed.ncbi.nlm.nih.gov/19164225/
   PubMed Web of Science ®Google Scholar
• Chen MK, Yasrebi M, Samii J, et al. The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer. Thyroid: offic j Am Thyroid Association [Internet]. 2012 [cited 2021 Nov 21];22(3):304–309. Available from: https://pubmed.ncbi.nlm.nih.gov/22300251/
   PubMed Web of Science ®Google Scholar
• Song H, Mosci C, Akatsu H, et al. Diagnostic 123I Whole Body Scan Prior to Ablation of Thyroid Remnant in Patients With Papillary Thyroid Cancer: Implications for Clinical Management. Clin Nucl Med [Internet]. 2018 [cited 2021 Nov 21];43(10):705–709. Available from: https://pubmed.ncbi.nlm.nih.gov/30153149/
   Web of Science ®Google Scholar
• Liu M, Cheng L, Jin Y, et al. Predicting 131I-avidity of metastases from differentiated thyroid cancer using 18F-FDG PET/CT in postoperative patients with elevated thyroglobulin. Sci Rep [Internet]. 2018 [cited 2023 Jun 13];8. Available from 1). Available from: https://pubmed.ncbi.nlm.nih.gov/29531251/
   Google Scholar
• Avram AM, Dewaraja YK. Thyroid Cancer Radiotheragnostics: the case for activity adjusted 131 I therapy. Clin Transl Imaging [Internet]. 2018 [cited 2021 Nov 20];6(5):335–346. Available from: https://pubmed.ncbi.nlm.nih.gov/30911535/
   PubMed Web of Science ®Google Scholar
• Barwick T, Murray I, Megadmi H, et al. Single photon emission computed tomography (SPECT)/computed tomography using Iodine-123 in patients with differentiated thyroid cancer: additional value over whole body planar imaging and SPECT. Eur J Endocrinol [Internet]. 2010 [cited 2023 Nov 15];162(6):1131–1139. Available from: https://pubmed.ncbi.nlm.nih.gov/20212015/
   PubMed Web of Science ®Google Scholar
• Campennì A, Ruggeri RM, Siracusa M, et al. Thyroglobulin Value Predict Iodine-123 Imaging Result in Differentiated Thyroid Cancer Patients. Cancers (Basel) [Internet]. 2023 [cited 2023 Nov 14];15(8):2242. Available from: https://pubmed.ncbi.nlm.nih.gov/37190170/
   PubMed Web of Science ®Google Scholar
• Campennì A, Ruggeri RM, Siracusa M, et al. Isthmus topography is a risk factor for persistent disease in patients with differentiated thyroid cancer. Eur J Endocrinol [Internet]. 2021 [cited 2023 Jan 21];185(3):397–404. Available from: https://pubmed.ncbi.nlm.nih.gov/34232125/
   PubMed Web of Science ®Google Scholar
• Banerjee M, Wiebel JL, Guo C, et al. Use of imaging tests after primary treatment of thyroid cancer in the United States: population based retrospective cohort study evaluating death and recurrence. BMJ [Internet]. 2016 [cited 2021 Nov 21];354. Available from i3839. Available from: https://pubmed.ncbi.nlm.nih.gov/27443325/
   PubMed Web of Science ®Google Scholar
• Gulec SA, Kuker RA, Goryawala M, et al. 124 I PET/CT in patients with differentiated thyroid cancer: clinical and quantitative image analysis. Thyroid: offic j Am Thyroid Association [Internet]. 2016 [cited 2024 Feb 24];26(3):441–448. Available from: https://pubmed.ncbi.nlm.nih.gov/26857905/
   PubMed Web of Science ®Google Scholar
• Santhanam P, Taieb D, Solnes L, et al. Utility of I-124 PET/CT in identifying radioiodine avid lesions in differentiated thyroid cancer: a systematic review and meta-analysis. Clin Endocrinol (Oxf) [Internet]. 2017 [cited 2021 Nov 20];86(5):645–651. Available from: https://pubmed.ncbi.nlm.nih.gov/28160320/
   PubMed Web of Science ®Google Scholar
• Albano D, Dondi F, Bellini P, et al. Biomarkers and Molecular Imaging in Postoperative DTC Management. In: Giovanella L, editor. Integrated Diagnostics and Theranostics of Thyroid Diseases [Internet]. Cham: Springer; 2023 [cited 2024 Feb 24]. p. 129–142. Available from: https://link.springer.com/chapter/10.1007/978-3-031-35213-3_8
   Google Scholar
• Sgouros G, Kolbert KS, Sheikh A, et al. Patient-Specific Dosimetry for 131I Thyroid Cancer Therapy Using 124I PET and 3-Dimensional-Internal Dosimetry (3D-ID) Software. J Nucl Med. 2004;45:1366–1372.
   PubMed Web of Science ®Google Scholar
• Wierts R, Brans B, Havekes B, et al. Dose–Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124 I PET/CT. J Nucl Med [Internet]. 2016 [cited 2024 Feb 24];57(7):1027–1032. Available from: https://pubmed.ncbi.nlm.nih.gov/26917706/
   PubMed Web of Science ®Google Scholar
• Freudenberg LS, Jentzen W, Petrich T, et al. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging [Internet]. 2010 [cited 2023 Mar 23];37(12):2267–2276. Available from: https://pubmed.ncbi.nlm.nih.gov/20661558/
   PubMed Web of Science ®Google Scholar
• Jentzen W, Verschure F, Van Zon A, et al. 124I PET Assessment of Response of Bone Metastases to Initial Radioiodine Treatment of Differentiated Thyroid Cancer. J Nucl Med [Internet]. 2016 [cited 2021 Nov 21];57(10):1499–1504. Available from: https://pubmed.ncbi.nlm.nih.gov/27199362/
   PubMed Web of Science ®Google Scholar
• Miller ME, Chen Q, Elashoff D, et al. Positron emission tomography and positron emission tomography-CT evaluation for recurrent papillary thyroid carcinoma: meta-analysis and literature review. Head Neck [Internet]. 2011 [cited 2021 Nov 20];33(4):562–565. Available from: https://pubmed.ncbi.nlm.nih.gov/20665734/
   PubMed Web of Science ®Google Scholar
• Schütz F, Lautenschläger C, Lorenz K, et al. Positron Emission Tomography (PET) and PET/CT in Thyroid Cancer: A Systematic Review and Meta-Analysis. Eur Thyroid J [Internet]. 2018 [cited 2021 Nov 20];7(1):13–20. Available from: https://pubmed.ncbi.nlm.nih.gov/29594049/
   PubMed Web of Science ®Google Scholar
• Kim SJ, Lee SW, Pak K, et al. Diagnostic performance of PET in thyroid cancer with elevated anti-Tg Ab. Endocr Relat Cancer [Internet]. 2018 [cited 2021 Nov 20];25(6):643–652. Available from: https://pubmed.ncbi.nlm.nih.gov/29559552/
   PubMed Web of Science ®Google Scholar
• Leboulleux S, Schroeder PR, Busaidy NL, et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab [Internet]. 2009 [cited 2023 Jun 8];94(4):1310–1316. Available from: https://pubmed.ncbi.nlm.nih.gov/19158200/
   PubMed Web of Science ®Google Scholar
• Giovanella L, Trimboli P, Verburg FA, et al. Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging [Internet]. 2013 [cited 2023 Aug 14];40(6):874–880. Available from: https://pubmed.ncbi.nlm.nih.gov/23463330/
   PubMed Web of Science ®Google Scholar
• Treglia G, Goichot B, Giovanella L, et al. Prognostic and predictive value of nuclear imaging in endocrine oncology. Endocrine [Internet]. 2020 [cited 2023 May 6];67(1):9–19. Available from: https://pubmed.ncbi.nlm.nih.gov/31734779/
   PubMed Web of Science ®Google Scholar
• Petranović Ovčariček P, Campenni A, de Keizer B, et al. Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer. Cancers (Basel) [Internet]. 2023 [cited 2023 Nov 14];15. Available from 17):4290. Available from: https://pubmed.ncbi.nlm.nih.gov/37686566/.
   PubMed Web of Science ®Google Scholar
• Deandreis D, Al Ghuzlan A, Leboulleux S, et al. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?. Endocr Relat Cancer [Internet]. 2011 [cited 2021 Nov 21];18(1):159–169. Available from: https://pubmed.ncbi.nlm.nih.gov/21118976/
   PubMed Web of Science ®Google Scholar
• Wells SA, Asa SL, Dralle H, et al. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid: Offic J Am Thyroid Association. 2015;25(6):567–610. doi: 10.1089/thy.2014.0335
   PubMed Web of Science ®Google Scholar
• Rasul S, Hartenbach S, Rebhan K, et al. [18F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery. Eur J Nucl Med Mol Imaging [Internet]. 2018 [cited 2021 Nov 21];45(12):2159. Available from:/pmc/articles/PMC6182401/
   PubMed Web of Science ®Google Scholar
• Cetani F, Marcocci C, Torregrossa L, et al. Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors. Endocr Relat Cancer. 2019;26(7):R441–R464. doi: 10.1530/ERC-19-0135
   PubMed Web of Science ®Google Scholar
• Fraser WD. Hyperparathyroidism. Lancet [Internet]. 2009 [cited 2019 Oct 28];374(9684):145–158. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19595349
   PubMed Web of Science ®Google Scholar
• Yeh MW, Ituarte PHG, Zhou HC, et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab [Internet]. 2013 [cited 2023 Nov 24];98(3):1122–1129. Available from: https://pubmed.ncbi.nlm.nih.gov/23418315/
   PubMed Web of Science ®Google Scholar
• Silverberg SJ, Lewiecki EM, Mosekilde L, et al. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94(2):351–365. doi: 10.1210/jc.2008-1760
   PubMed Web of Science ®Google Scholar
• Bilezikian JP, Bandeira L, Khan A, et al. Hyperparathyroidism. Lancet. 2018;391(10116):168–178. doi: 10.1016/S0140-6736(17)31430-7
   PubMed Web of Science ®Google Scholar
• Phitayakorn R, McHenry CR. Incidence and location of ectopic abnormal parathyroid glands. Am J Surg. 2006;191(3):418–423. doi: 10.1016/j.amjsurg.2005.10.049
   PubMed Web of Science ®Google Scholar
• Akerström G, Malmaeus J, Bergström R. Surgical anatomy of human parathyroid glands. Surgery. 1984;95(1):14–21.
   PubMed Web of Science ®Google Scholar
• Wang C. The anatomic basis of parathyroid surgery. Ann Surg [Internet]. 1976 [cited 2019 Nov 30];183(3):271–275. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1259483
   PubMed Web of Science ®Google Scholar
• Duan K, Gomez Hernandez K, Mete O. Clinicopathological correlates of hyperparathyroidism. J Clin Pathol. 2015;68(10):771–787. doi: 10.1136/jclinpath-2015-203186
   PubMed Web of Science ®Google Scholar
• Singh Ospina NM, Rodriguez-Gutierrez R, Maraka S, et al. Outcomes of Parathyroidectomy in Patients with Primary Hyperparathyroidism: A Systematic Review and Meta-analysis. World J Surg [Internet]. 2016 [cited 2020 Aug 3];40:2359–2377. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27094563
   PubMed Web of Science ®Google Scholar
• Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3561–3569. doi: 10.1210/jc.2014-1413
   PubMed Web of Science ®Google Scholar
• Udelsman R, Lin Z, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg. 2011;253(3):585–591. doi: 10.1097/SLA.0b013e318208fed9
   PubMed Web of Science ®Google Scholar
• Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg. 2002;235(5):665. doi: 10.1097/00000658-200205000-00008
   PubMed Web of Science ®Google Scholar
• Jinih M, O’Connell E, O’Leary DP, et al. Focused Versus Bilateral Parathyroid Exploration for Primary Hyperparathyroidism: A Systematic Review and Meta-analysis. Ann Surg Oncol [Internet]. 2017 [cited 2023 Dec 2];24(7):1924–1934. Available from: https://pubmed.ncbi.nlm.nih.gov/27896505/
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surg [Internet]. 2016 [cited 2019 Dec 1];151(10):959–968. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27532368
   PubMed Web of Science ®Google Scholar
• Hayakawa N, Nakamoto Y, Kurihara K, et al. A comparison between 11C-methionine PET/CT and MIBI SPECT/CT for localization of parathyroid adenomas/hyperplasia. Nucl Med Commun. 2015;36(1):53–59. doi: 10.1097/MNM.0000000000000216
   PubMed Web of Science ®Google Scholar
• Petranović Ovčariček P, Giovanella L, Carrió Gasset I, et al. The EANM practice guidelines for parathyroid imaging. Eur J Nucl Med Mol Imaging [Internet]. 2021 [cited 2022 Jan 24];48(9):2801–2822. Available from: https://pubmed.ncbi.nlm.nih.gov/33839893/
   PubMed Web of Science ®Google Scholar
• Castellana M, Virili C, Palermo A, et al. Primary hyperparathyroidism with surgical indication and negative or equivocal scintigraphy: safety and reliability of PTH washout. A systematic review and meta-analysis. Eur J Endocrinol. 2019;181(3):245–253. doi: 10.1530/EJE-19-0160
   PubMed Web of Science ®Google Scholar
• Treglia G, Sadeghi R, Schalin-Jäntti C, et al. Detection rate of 99m Tc-MIBI single photon emission computed tomography (SPECT)/CT in preoperative planning for patients with primary hyperparathyroidism: A meta-analysis. Head & Neck [Internet]. 2016 [cited 2019 Nov 7];38(S1):E2159–E2172. doi: http://doi.org/10.1002/hed.24027
   PubMedGoogle Scholar
• Medas F, Erdas E, Longheu A, et al. Retrospective evaluation of the pre- and postoperative factors influencing the sensitivity of localization studies in primary hyperparathyroidism. Int J Surg. 2016;25:82–87. doi: 10.1016/j.ijsu.2015.11.045
   PubMed Web of Science ®Google Scholar
• Nichols KJ, Tomas MB, Tronco GG, et al. Sestamibi parathyroid scintigraphy in multigland disease. Nucl Med Commun. 2012;33(1):43–50. doi: 10.1097/MNM.0b013e32834bfeb1
   PubMed Web of Science ®Google Scholar
• Krakauer M, Wieslander B, Myschetzky PS, et al. A prospective comparative study of parathyroid dual-phase scintigraphy, dual-isotope subtraction scintigraphy, 4D-CT, and ultrasonography in primary hyperparathyroidism. Clin Nucl Med. 2016;41(2):93–100. doi: 10.1097/RLU.0000000000000988
   PubMed Web of Science ®Google Scholar
• Woods A-M, Bolster AA, Han S, et al. Dual-isotope subtraction SPECT-CT in parathyroid localization. Nucl Med Commun [Internet]. 2017 [cited 2019 Dec 5];38(12):1047–1054. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28984813
   PubMed Web of Science ®Google Scholar
• Kunstman JW, Kirsch JD, Mahajan A, et al. Parathyroid localization and implications for clinical management. J Clin Endocrinol Metab. 2013;98(3):902–912. doi: 10.1210/jc.2012-3168
   PubMed Web of Science ®Google Scholar
• Palestro CJ, Tomas MB, Tronco GG. Radionuclide imaging of the parathyroid glands. Semin Nucl Med. 2005;35(4):266–276. doi: 10.1053/j.semnuclmed.2005.06.001
   PubMed Web of Science ®Google Scholar
• Ishibashi M, Nishida H, Hiromatsu Y, et al. Comparison of technetium-99m-MIBI, technetium-99m-tetrofosmin, ultrasound and MRI for localization of abnormal parathyroid glands. J Nucl Med. 1998;39(2):320–324.
   PubMed Web of Science ®Google Scholar
• Wakamatsu H, Noguchi S, Yamashita H, et al. Technetium-99m tetrofosmin for parathyroid scintigraphy: a direct comparison with 99mTc-MIBI, 201Tl, MRI and US. Eur J Nucl Med. 2001;28(12):1817–1827. doi: 10.1007/s002590100627
   PubMedGoogle Scholar
• Petranović Ovčariček P, Giovanella L, Hindie E, et al. An essential practice summary of the new EANM guidelines for parathyroid imaging. Q J Nucl Med Mol Imaging [Internet]. 2022 [cited 2023 Nov 27];66(2):93–103. Available from: https://pubmed.ncbi.nlm.nih.gov/35166093/
   PubMed Web of Science ®Google Scholar
• Treglia G, Piccardo A, Imperiale A, et al. Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2019;46(3):751–765. doi: 10.1007/s00259-018-4123-z
   PubMed Web of Science ®Google Scholar
• Whitman J, Allen IE, Bergsland EK, et al. Assessment and Comparison of 18 F-Fluorocholine PET and 99m Tc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis. J Nucl Med [Internet]. 2021 [cited 2021 Jan 16]; Available from 62(9):1285–1291. Available from: http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.120.257303
   PubMed Web of Science ®Google Scholar
• Giovanella L, Bacigalupo L, Treglia G, et al. Will 18F-fluorocholine PET/CT replace other methods of preoperative parathyroid imaging?. Endocrine [Internet]. 2021 [cited 2021 Apr 9];71(2):285–297. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32892309
   PubMed Web of Science ®Google Scholar
• López-Mora DA, Sizova M, Estorch M, et al. Superior performance of 18F-fluorocholine digital PET/CT in the detection of parathyroid adenomas. Eur J Nucl Med Mol Imaging. 2020;47(3):572–578. doi: 10.1007/s00259-020-04680-7
   PubMed Web of Science ®Google Scholar
• Imperiale A, Taïeb D, Hindié E. 18F-Fluorocholine PET/CT as a second line nuclear imaging technique before surgery for primary hyperparathyroidism. Eur J Nucl Med Mol Imaging. 2018;45(4):654–657. doi: 10.1007/s00259-017-3920-0
   PubMed Web of Science ®Google Scholar
• Piccardo A, Bottoni G, Boccalatte LA, et al. Head-to-head comparison among 18 F-choline PET/CT, 4D contrast-enhanced CT, and 18 F-choline PET/4D contrast-enhanced CT in the detection of hyperfunctioning parathyroid glands: a systematic review and meta-analysis. Endocrine [Internet]. 2021 [cited 2022 Jan 23];74(2):404–412. Available from: https://pubmed.ncbi.nlm.nih.gov/34173158/
   PubMed Web of Science ®Google Scholar
• Kluijfhout WP, Pasternak JD, Gosnell JE, et al. 18 F fluorocholine PET/MR imaging in patients with primary hyperparathyroidism and inconclusive conventional imaging: a prospective Pilot study. Radiology. 2017;284(2):460–467. doi: 10.1148/radiol.2016160768
   PubMed Web of Science ®Google Scholar
• Noltes M, Rotstein L, Eskander A, et al. 18F-fluorocholine PET/MRI versus ultrasound and sestamibi for the localization of parathyroid adenomas. Langenbecks Arch Surg [Internet]. 2023 [cited 2023 Nov 23];408. Available from 1). Available from: https://pubmed.ncbi.nlm.nih.gov/37079138/
   PubMed Web of Science ®Google Scholar
• Huellner MW, Aberle S, Sah B-R, et al. Visualization of Parathyroid Hyperplasia Using 18F-Fluorocholine PET/MR in a Patient With Secondary Hyperparathyroidism. Clin Nucl Med [Internet]. 2016 [cited 2020 Aug 3];41(3):e159–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26462047
   PubMed Web of Science ®Google Scholar
• Huber GF, Hüllner M, Schmid C, et al. Benefit of 18F-fluorocholine PET imaging in parathyroid surgery. Eur Radiol [Internet]. 2018 [cited 2020 Aug 4];28(6):2700–2707. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29372312
   PubMed Web of Science ®Google Scholar
• Alharbi AA, Alshehri FM, Albatly AA, et al. [18F]Fluorocholine Uptake of Parathyroid Adenoma Is Correlated with Parathyroid Hormone Level. Mol Imaging Biol [Internet]. 2018 [cited 2020 Aug 4];20(5):857–867. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29508264
   PubMed Web of Science ®Google Scholar
• Parvinian A, Martin-Macintosh EL, Goenka AH, et al. 11 C-Choline PET/CT for Detection and Localization of Parathyroid Adenomas. Am J Roentgenol [Internet]. 2018 [cited 2019 Nov 8];210(2):418–422. Available from: https://www.ajronline.org/doi/10.2214/AJR.17.18312
   PubMed Web of Science ®Google Scholar
• Noltes ME, Kruijff S, Jansen L, et al. A retrospective analysis of the diagnostic performance of 11C-choline PET/CT for detection of hyperfunctioning parathyroid glands after prior negative or discordant imaging in primary hyperparathyroidism. EJNMMI Res 2021 [Internet]. 2021 [cited 2021 Sep 14];11(1):1–9. Available from: https://ejnmmires.springeropen.com/articles/10.1186/s13550-021-00778-7
   Google Scholar
• Otto D, Boerner AR, Hofmann M, et al. Pre-operative localisation of hyperfunctional parathyroid tissue with 11C-methionine PET. Eur J Nucl Med Mol Imaging. 2004;31(10):1405–1412. doi: 10.1007/s00259-004-1610-1
   PubMed Web of Science ®Google Scholar
• Kluijfhout WP, Pasternak JD, Drake FT, et al. Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. Langenbecks Arch Surg. 2016;401(7):925–935. doi: 10.1007/s00423-016-1425-0
   PubMed Web of Science ®Google Scholar
• Bioletto F, Barale M, Parasiliti-Caprino M, et al. Comparison of the diagnostic accuracy of 18F-Fluorocholine PET and 11C-Methionine PET for parathyroid localization in primary hyperparathyroidism: a systematic review and meta-analysis. Eur J Endocrinol [Internet]. 2021 [cited 2022 Jan 23];185(1):109–120. Available from: https://pubmed.ncbi.nlm.nih.gov/33886494/
   PubMed Web of Science ®Google Scholar
• Alabed YZ, Rakheja R, Novales-Diaz JA, et al. Recurrent parathyroid carcinoma appearing as FDG negative but MIBI positive. Clin Nucl Med. 2014;39(7):e362–4. doi: 10.1097/RLU.0000000000000357
   PubMed Web of Science ®Google Scholar
• Kim SS, Jeon YK, Lee SH, et al. Distant subcutaneous recurrence of a parathyroid carcinoma: abnormal uptakes in the 99mTc-sestamibi scan and 18F-FDG PET/CT imaging. Korean J Intern Med. 2014;29(3):383. doi: 10.3904/kjim.2014.29.3.383
   PubMed Web of Science ®Google Scholar
• Cao C, Dou C, Chen F, et al. An unusual mediastinal parathyroid carcinoma coproducing PTH and PTHrP: a case report. Oncol Lett. 2016;11(6):4113–4116. doi: 10.3892/ol.2016.4548
   PubMed Web of Science ®Google Scholar
• Singh P, Vadi SK, Saikia UN, et al. Minimally invasive parathyroid carcinoma—A missing entity between parathyroid adenoma and carcinoma: Scintigraphic and histological features. Clin Endocrinol (Oxf). 2019;91(6):842–850. doi: 10.1111/cen.14088
   PubMed Web of Science ®Google Scholar
• Haciyanli M, Oruk G, Ucarsoy AA, et al. Multiglandular parathyroid carcinoma: case report and review of the literature. Endocr Pract. 2011;17(4):e79–83. doi: 10.4158/EP11037.CRR
   PubMedGoogle Scholar
• Ferraro V, Sgaramella LI, Di Meo G, et al. Current concepts in parathyroid carcinoma: a single Centre experience. BMC Endocr Disord. 2019;19(S1):46. doi: 10.1186/s12902-019-0368-1
   PubMedGoogle Scholar
• Zhang M, Sun L, Rui W, et al. Semi-quantitative analysis of 99mTc-sestamibi retention level for preoperative differential diagnosis of parathyroid carcinoma. Quant Imaging Med Surg. 2019;9(8):1394–1401. doi: 10.21037/qims.2019.07.02
   PubMed Web of Science ®Google Scholar
• Morand GB, Rupp NJ, Huellner MW, et al. Transnasal-Transpterygoid Endoscopic Removal of an 18 F–Choline-Avid parathyroid carcinoma metastasis in the Skull Base. JAMA Otolaryngology–Head & Neck Surg. 2019;145(10):978. doi: 10.1001/jamaoto.2019.2352
   PubMed Web of Science ®Google Scholar
• Deandreis D, Terroir M, Al Ghuzlan A, et al. 18Fluorocholine PET/CT in parathyroid carcinoma: a new tool for disease staging? Eur J Nucl Med Mol Imaging. 2015;42(12):1941–1942. doi: 10.1007/s00259-015-3130-6
   PubMed Web of Science ®Google Scholar
• Hatzl M, Röper-Kelmayr JC, Fellner FA, et al. 18F-Fluorocholine, 18F-FDG, and 18F-Fluoroethyl tyrosine PET/CT in parathyroid cancer. Clin Nucl Med. 2017;42(6):448–450. doi: 10.1097/RLU.0000000000001652
   PubMed Web of Science ®Google Scholar
• Rodrigo JP, Hernandez-Prera JC, Randolph GW, et al. Parathyroid cancer: An update. Cancer Treat Rev. 2020;86:102012. doi: 10.1016/j.ctrv.2020.102012
   PubMed Web of Science ®Google Scholar